What is peptide cycling, and why do researchers use it?

Peptide cycling alternates active periods (on) with abstinent periods (off). Three rationales dominate the practice. First, receptor pharmacology: some peptides, especially GH secretagogues, can drive receptor desensitization or tachyphylaxis under continuous use, and structured off-periods let receptors resensitize before exposure resumes. Second, biological timelines: healing peptides like BPC-157 and TB-500 are typically studied for the duration of the process being investigated, such as tissue repair, with cycling aligning exposure to those windows. Third, research design: on/off periods create natural comparison windows that help distinguish compound effects from baseline biology — often the cleanest reason of all. What doesn't exist is controlled human comparison of cycling protocols; community strategies derive from preclinical data, mechanistic reasoning, and extrapolation from related clinical compounds.

How long should a typical peptide cycle last?

Duration tracks compound class and research objective — and honest answers name their evidence tier. For GH secretagogues: CJC-1295 with DAC runs 8–12 weeks on, 4–6 weeks off (its 6–8 day half-life sustains IGF-1 elevation well past each injection [PMID: 16352683]); ipamorelin allows shorter patterns like 5 days on/2 days off or 4–8 weeks on, 2–4 weeks off (its 2-hour half-life means rapid receptor recovery [PMID: 9849822]); GHRP-6 commonly runs 4–8 weeks on, 2–4 weeks off given its broader cortisol and appetite effects needing management [PMID: 9285939]. For healing peptides, duration aligns with the biological process under study: BPC-157 spans 4–12 weeks on for tissue repair work with off-periods reserved for comparison data; TB-500 uses a 4–6 week loading phase followed by 4–8 weeks maintenance, then an off-period. All durations are pharmacokinetic extrapolations and mechanistic reasoning, not validated comparatives — no controlled human trial has established optimal cycle length for any of them.

Does BPC-157 need to be cycled?

The pharmacological case is weaker than for secretagogues, and that's by mechanism rather than opinion. BPC-157 doesn't stimulate a receptor in the classical agonist sense — it modulates existing growth factor pathways (VEGF, EGF) and the nitric oxide system [PMID: 21030672, PMID: 25415472, PMID: 23755725], leaving the tachyphylaxis machinery little to grip. Its unusually robust safety record removes the other common motivation: over 100 preclinical studies conducted without identifying a minimum toxic dose [PMC: 12446177], meaning safety-based cycling isn't pharmacologically motivated either. What remains is research design — creating on/off comparison windows to assess whether observed effects persist after withdrawal. That's a methodological choice worth making deliberately, not a requirement imposed by the molecule itself.

Can different peptides be cycled on different schedules simultaneously?

Yes, and the choice between independent and synchronized schedules shapes what your data can tell you. Independent cycling gives each class its own calendar and preserves attribution: continuous BPC-157 beside 8-week cycled CJC-1295/ipamorelin reveals whether healing effects persist through the secretagogue off-period without confounding from shared withdrawal. Synchronized cycling puts both classes on together and off together — simpler logistics and cleaner on/off comparisons, at the cost of not knowing which compound caused which change when both were active. Injection-site burden factors in regardless of philosophy: researchers administering multiple peptides subcutaneously benefit from rotating sites and letting tissue recover during off-periods, whatever the pharmacological rationale.

What happens when a peptide cycle ends — do effects persist?

Persistence depends on compound and process, and the differences are instructive. For GH secretagogues, changes mostly reverse: GH and IGF-1 return toward baseline within 1–3 weeks of discontinuation — faster for ipamorelin, slower for CJC-1295 with DAC given its long half-life — taking water retention, body-composition shifts, and insulin sensitivity changes with them as hormones normalize [PMID: 16352683]. For healing peptides the question splits: structural tissue changes — new collagen, angiogenesis, tissue remodeling — physically persist beyond withdrawal because the tissue itself has been altered, while support for ongoing processes (chronic inflammation modulation, for instance) may fade during the off-period. Weight-management compounds set the cautionary example: semaglutide discontinuation led participants to regain roughly two-thirds of lost weight within one year [PMID: 35441470], steering research toward maintenance dosing strategies rather than classic cycling.

Is there evidence that cycling improves peptide research outcomes?

No controlled human study has compared cycling against continuous administration for any research peptide — full stop, and that absence defines the field. Supporting evidence stays indirect, drawn from three sources: receptor pharmacology studies demonstrating desensitization mechanisms under chronic agonist exposure, pharmacokinetic data showing sustained hormonal effects that engage feedback loops, and general endocrine principles of hypothalamic-pituitary axis regulation. The indirect case is strongest for GH secretagogues, where desensitization management is mechanistically sound even without direct human validation; weakest for healing peptides, where cycling rests on treatment timelines and design preference rather than demonstrated need. That gap doubles as an opening — researchers who document and publish cycling outcomes, both on-period effects and off-period changes, will materially advance the evidence base the entire field currently borrows against.

Research Guide

Peptide Cycling Strategies: On/Off Protocols in Research

Peptide cycling protocols: on/off period rationale and compound-specific strategies for GH secretagogues and healing peptides. PubMed citations.

Last updated Jul 23, 2026 12 min read

Ask five researchers how long a peptide cycle should run and you'll get five confident answers backed by zero controlled trials. Peptide cycling — alternating between active periods ("on") and abstinence ("off") — is among the most discussed and least formally studied questions in protocol design.

That confidence gap has a reason. Unlike pharmaceutical drugs, which earn their dosing schedules through rigorous clinical comparison, most research peptides have no published human dosing protocols at all. The cycling strategies circulating in research communities derive from preclinical animal data, mechanistic reasoning about receptor pharmacology, and extrapolation from related clinical compounds — not from controlled studies comparing cycling against continuous administration.

This guide lays out the scientific rationale honestly, organizes strategies by compound class, and documents what published literature actually supports. Five compounds anchor the discussion — ** BPC-157 , TB-500 , CJC-1295 , Ipamorelin , and GHRP-6 ** — spanning three distinct cycling contexts: GH secretagogue cycling, healing peptide cycling, and the mechanistic divide separating them.

All citations reference peer-reviewed studies indexed in PubMed. For side effects during on-periods, see the Peptide Side Effects guide; for biomarker tracking across cycles, the Peptide Safety Monitoring guide.

Overview

Cycling isn't a peptide invention. Corticosteroids, anabolic steroids, beta-agonists, and many receptor-targeting drugs employ on/off strategies to manage tachyphylaxis, receptor downregulation, and cumulative side effects. The shared principle: continuous stimulation of a biological pathway yields diminishing returns as the system adapts, while periodic withdrawal lets it resensitize.

Tachyphylaxis — rapid decrease in response following repeated administration — supplies the pharmacological backbone. Continuous agonist exposure triggers several adaptation mechanisms at once: receptor internalization (the cell pulls receptors off its surface), desensitization (receptors transduce signals less efficiently), and downstream pathway dampening (intracellular cascades recalibrate to the new baseline).

Compound classes diverge sharply from there. Growth hormone secretagogues — CJC-1295 , Ipamorelin , GHRP-6 — operate through GHS-R1a and GHRH receptors embedded in the hypothalamic-pituitary axis, a system with well-documented feedback loops that adjust sensitivity under chronic stimulation. Research suggests continuous secretagogue administration can reduce GH pulse amplitude over time as pituitary somatotrophs adapt — a direct, mechanism-based argument for structured off-periods.

Healing peptides play by other rules entirely. BPC-157 modulates growth factor pathways (VEGF, EGF) and the nitric oxide system; TB-500 regulates intracellular actin dynamics. Neither stimulates a receptor in the classical agonist sense, so tachyphylaxis logic transfers only weakly. Cycling decisions here follow practical timelines of the biological process being studied rather than receptor pharmacology.

A third category is emerging around weight-management peptides like semaglutide and tirzepatide , where the research question became what happens after discontinuation. A 2022 study found participants who stopped semaglutide regained roughly two-thirds of lost weight within one year — a finding pushing interest toward maintenance dosing strategies rather than traditional cycling.

One limitation frames everything that follows, and stating it plainly is part of using this guide well: no controlled human trial has directly compared cycling protocols for any research peptide. Every strategy below represents a hypothesis informed by science — pharmacokinetics, receptor biology, adjacent clinical experience — and never a validated protocol. Researchers who treat them that way design better studies; researchers who treat them as settled regimens inherit someone else's assumptions.

Compounds in This Guide

BPC-157

Gastrointestinal protection & systemic tissue repair

Full profile â†’

BPC-157 belongs to a fundamentally different cycling category than the secretagogues — and understanding why prevents applying the wrong logic to the wrong compound.

It doesn't stimulate a receptor in the classical agonist sense. It appears instead to modulate existing growth factor pathways — upregulating VEGF and EGF, activating mTOR and FAK-paxillin signaling [PMID: 21030672, PMID: 25415472] — and interacts with the nitric oxide system . Amplifying signals the body already runs introduces no novel stimulus for a receptor to adapt to, so the tachyphylaxis rationale driving secretagogue cycles applies only weakly.

What structures BPC-157 protocols instead is the timeline of the biological process under study. Tendon-healing research, for example, orients the on-period around proliferative and remodeling phases — typically 6–12 weeks in animal models — then uses the off-period as a comparison window assessing whether healing effects persist after withdrawal.

Patterns reflect that orientation: continuous use across 4–12 weeks aligned with repair timelines, then an off-period of equal or shorter duration serving as the comparison window. Some researchers borrow a loading/maintenance structure — higher doses weeks 1–4, lower maintenance through week 12, then off — though that approach imports supplement-industry and pharmaceutical convention rather than anything derived from BPC-157 -specific pharmacological data, and it should be labeled as such in any protocol.

Safety data rarely motivates cycling here either: 100+ preclinical studies without identifying a minimum toxic dose, no teratogenic, genotoxic, anaphylactic, or local toxic effects reported [PMC: 12446177], three small human pilots reporting no adverse effects. Such a wide therapeutic window makes research design — clean on/off comparisons — the primary argument for cycling, not safety management.

One open pharmacological question could eventually change that: BPC-157 's modulation of nitric oxide signaling might theoretically drive compensatory NOS-expression changes under continuous use. Theoretically — nothing in the literature documents it yet.

gut-healing tendon-repair wound-healing injury-recovery

TB-500

Systemic tissue repair & angiogenesis

Full profile â†’

TB-500 inherits its cycling profile from its parent molecule's biology: Thymosin Beta-4 lives in virtually every nucleated cell, working intracellularly through actin regulation rather than surface receptor stimulation.

That intracellular address breaks the classical tachyphylaxis model before it starts — there is no receptor to downregulate. Actin dynamics respond to the cell's internal state, and ** TB-500 modulates a pool of actin the cell continuously produces and degrades** . Desensitization logic simply lacks a handle to grab.

Practical protocol considerations and wound-healing biology fill the vacuum. Preclinical patterns commonly run a loading phase (4–6 weeks, higher doses) into maintenance (4–8 weeks, lower doses) and finally an off-period — a structure borrowed from Phase II-era Tβ4 regimens built around expected tissue repair timelines rather than receptor kinetics.

Systemic distribution adds a design consideration unique to this compound, and it's one easy to overlook until data interpretation day. Because actin sits in every nucleated cell, on-period exposure touches multiple tissue systems simultaneously — meaning off-period assessments should acknowledge that cardiac tissue, skeletal muscle, and others were exposed too, not just the tendon under study. Attribution narrows accordingly.

The theoretical neoplasia concern sometimes enters cycling arguments: promoting migration and angiogenesis could theoretically influence pre-existing abnormal cells. The underlying literature genuinely disagrees with itself — some laboratory studies suggest Tβ4 may promote spread of certain cancer cell lines while others show inhibition of tumor proliferation — and no human evidence links TB-500 to cancer development. Absent long-term data, structured off-periods function as reasonable caution margin rather than demonstrated necessity.

Phase II Tβ4 trials reinforce that framing rather than undermining it: a favorable safety profile with no serious drug-related adverse events and adverse event rates matching placebo groups . Cycling here is a design choice wearing safety clothes — defensible, useful for clean on/off comparisons, but not a demonstrated requirement.

wound-healing tendon-repair injury-recovery

CJC-1295

Growth hormone-releasing hormone analogue

Full profile â†’

CJC-1295 makes the strongest case for deliberate cycling of any compound in this guide — because its mechanism engages hypothalamic-pituitary feedback longer and harder than anything else discussed here.

The DAC version carries a half-life of roughly 6–8 days, keeping IGF-1 elevated for over a week after one injection. Somatotrophs face continuous stimulation throughout, which research suggests can reduce GH pulse amplitude over time as negative feedback adjusts baseline secretion . Teichman et al.'s 2006 dose-escalation study documented IGF-1 remaining above baseline for 7–11 days — the sustained pharmacodynamic footprint that puts cycling on the table at all.

Modified GRF 1-29 (no DAC) lives differently. Its ~30-minute half-life produces physiological pulses rather than tonic elevation; the pituitary recovers between doses, so the cycling case for the non-DAC form is considerably weaker. Paired with a GHRP, modified GRF 1-29 often maintains pulsatility without the desensitization concerns attached to sustained-release formulations.

The pattern most discussed for CJC-1295 with DAC runs 8–12 weeks on followed by 4–6 weeks off: enough sustained elevation to produce measurable IGF-1 effects, then enough clearance time for levels to drift back to baseline as somatotrophs resensitize.

Monitoring earns its keep during these cycles precisely because metabolic stakes run higher. Fasting glucose, fasting insulin, and HbA1c measured at baseline, mid-on-period, and post-off track insulin sensitivity changes; IGF-1 at the same points confirms pharmacodynamic effect during on-periods and return to baseline during off-periods. Water retention — the most common side effect — typically appears in the first 2–4 weeks and deserves tracking via body weight and subjective edema assessment .

What nobody has done is compare protocols directly: 8-on/4-off versus 12-on/6-off exists nowhere in controlled human data. Those durations are extrapolations from the compound's pharmacokinetic profile and general endocrine cycling principles — reasonable scaffolding, and honest protocols say so rather than presenting them as established regimens.

muscle-growth fat-loss anti-aging

Ipamorelin

Selective growth hormone secretagogue

Full profile â†’

Ipamorelin is the secretagogue least likely to need aggressive cycling — and the reason traces straight back to its mechanism.

With a half-life near 2 hours, it fires a sharp GH pulse and steps aside, letting somatotrophs recover fully between doses instead of facing days of tonic elevation like CJC-1295 with DAC. Raun et al. showed dose-dependent GH release comparable to GHRP-6 but without significant ACTH or cortisol elevation even at doses exceeding 200 times the effective threshold — selectivity that plausibly lowers the pituitary stress driving desensitization in less selective compounds.

Ipamorelin 's cycling rationale therefore runs more practical than pharmacological: aligning exposure with experimental timelines, testing whether GH-dependent effects persist during off-periods, or benchmarking on-period biomarkers against baseline. Common patterns include 5 days on/2 days off (a weekday rhythm), 4–6 weeks on/2–4 weeks off, or continuous use over shorter studies.

Stacked with CJC-1295 , ipamorelin inherits the partner's schedule. If the stack includes CJC-1295 with DAC, the 8–12 week on/4–6 week off framework governs both. With modified GRF 1-29, short half-lives across the board make continuous use more defensible, punctuated by off-periods for biomarker comparison.

Side effects barely pressure the decision either way: headache, injection-site irritation, mild nausea, occasional transient flushing — with water retention softer than CJC-1295 's thanks to brief GH elevation per dose . A mild profile reduces the pharmacological urgency of cycling, leaving protocol design free to decide on purely scientific grounds.

muscle-growth fat-loss sleep

GHRP-6

Ghrelin mimetic hexapeptide — strongest appetite stimulation among GHRPs

Full profile â†’

GHRP-6 complicates the cycling picture in productive ways — broader receptor activity means both a stronger rationale for off-periods and more variables to manage during them.

First in class to prove GH release through a non-GHRH pathway (via ghrelin receptor GHS-R1a activation), GHRP-6 never received ipamorelin 's selective engineering. It also activates pathways producing significant appetite stimulation — the strongest orexigenic effect in its class — alongside cortisol elevation and prolactin release . Those hormonal extras are dose-dependent and cumulative, which strengthens the structural case for rest periods.

The appetite effect alone reshapes study design. Direct ghrelin-receptor activation in hypothalamic feeding centers can substantially alter food intake at typical research doses (100–300 mcg), confounding any measurement touching body composition, metabolism, or weight. Structured off-periods let researchers separate GH-mediated effects from appetite-mediated ones by comparing on-period data (GH plus appetite) against off-period normalization.

Common patterns run 4–8 week on-periods against 2–4 week off-periods, or the 5-days-on/2-days-off rhythm some researchers use to manage cumulative effects while keeping regular GH stimulation in the data. Off-period length should respect an asymmetry that short half-lives hide: the compound itself clears fast (elimination-phase half-life ~20 minutes), but downstream hormonal effects — cortisol rhythm normalization, appetite regulation — may take 1–2 weeks to fully normalize. Cutting off-periods too short measures recovery that hasn't actually finished.

One theoretical wrinkle closes the section: GHRP-6 shares GHS-R1a with ipamorelin and GHRP-2, making cross-tachyphylaxis plausible when switching compounds without an intervening off-period. The evidence remains theoretical — shared-receptor logic rather than demonstrated experiment — but it argues for breathing room between class members.

appetite-stimulation muscle-growth gastrointestinal-motility

How They Work Together

Combining Classes Means Combining Clocks

Secretagogue cycling and healing-peptide cycling serve different purposes — so combined protocols must design each cycle independently before deciding whether they share a calendar.

Secretagogues cycle to manage receptor desensitization and hormonal feedback: on-periods elevate GH and IGF-1, off-periods let the pituitary axis resensitize. Cycle length follows the compound's pharmacokinetics — CJC-1295 with DAC needs longer windows than ipamorelin because sustained receptor engagement takes longer to unwind.

Healing peptides cycle to align with biological process timelines and attribution needs: on-periods cover expected tissue repair duration, off-periods test persistence and provide comparison data. Receptor desensitization barely features, because neither compound stimulates receptors classically.

Put both classes in one protocol and two architectures emerge, each with trade-offs. Independent cycling (continuous BPC-157 beside cycled CJC-1295 / ipamorelin ) preserves attribution — observed effects map onto whichever class was active. Synchronized cycling (both on together, both off together) simplifies logistics and cleans up on/off comparisons while blurring which compound drove which change.

Monitoring follows class boundaries, and keeping them straight prevents misreading data. Secretagogue on-periods prioritize IGF-1, fasting glucose, and fasting insulin; healing-peptide on-periods prioritize markers matched to tissue — inflammatory panels (CRP, ESR) for inflammation research, imaging for structural repair, functional tests for performance studies. Off-periods repeat the same panels to establish what persists after withdrawal versus what faded with it.

One practical benefit deserves mention precisely because it ignores pharmacology entirely: injection-site load. Multiple subcutaneous compounds accumulate local reactions over weeks of daily access; rotating sites and letting tissue recover during off-periods reduces that burden regardless of why you're cycling — a logistics dividend the receptor biologists never promised.

Frequently Asked Questions

: Peptide cycling alternates active periods (on) with abstinent periods (off). Three rationales dominate the practice. First, receptor pharmacology: some peptides, especially GH secretagogues, can drive receptor desensitization or tachyphylaxis under continuous use, and structured off-periods let receptors resensitize before exposure resumes. Second, biological timelines: healing peptides like BPC-157 and TB-500 are typically studied for the duration of the process being investigated, such as tissue repair, with cycling aligning exposure to those windows. Third, research design: on/off periods create natural comparison windows that help distinguish compound effects from baseline biology — often the cleanest reason of all. What doesn't exist is controlled human comparison of cycling protocols; community strategies derive from preclinical data, mechanistic reasoning, and extrapolation from related clinical compounds.
: Duration tracks compound class and research objective — and honest answers name their evidence tier. For GH secretagogues: CJC-1295 with DAC runs 8–12 weeks on, 4–6 weeks off (its 6–8 day half-life sustains IGF-1 elevation well past each injection [PMID: 16352683]); ipamorelin allows shorter patterns like 5 days on/2 days off or 4–8 weeks on, 2–4 weeks off (its 2-hour half-life means rapid receptor recovery [PMID: 9849822]); GHRP-6 commonly runs 4–8 weeks on, 2–4 weeks off given its broader cortisol and appetite effects needing management [PMID: 9285939]. For healing peptides, duration aligns with the biological process under study: BPC-157 spans 4–12 weeks on for tissue repair work with off-periods reserved for comparison data; TB-500 uses a 4–6 week loading phase followed by 4–8 weeks maintenance, then an off-period. All durations are pharmacokinetic extrapolations and mechanistic reasoning, not validated comparatives — no controlled human trial has established optimal cycle length for any of them.
: The pharmacological case is weaker than for secretagogues, and that's by mechanism rather than opinion. BPC-157 doesn't stimulate a receptor in the classical agonist sense — it modulates existing growth factor pathways (VEGF, EGF) and the nitric oxide system [PMID: 21030672, PMID: 25415472, PMID: 23755725], leaving the tachyphylaxis machinery little to grip. Its unusually robust safety record removes the other common motivation: over 100 preclinical studies conducted without identifying a minimum toxic dose [PMC: 12446177], meaning safety-based cycling isn't pharmacologically motivated either. What remains is research design — creating on/off comparison windows to assess whether observed effects persist after withdrawal. That's a methodological choice worth making deliberately, not a requirement imposed by the molecule itself.
: Yes, and the choice between independent and synchronized schedules shapes what your data can tell you. Independent cycling gives each class its own calendar and preserves attribution: continuous BPC-157 beside 8-week cycled CJC-1295/ipamorelin reveals whether healing effects persist through the secretagogue off-period without confounding from shared withdrawal. Synchronized cycling puts both classes on together and off together — simpler logistics and cleaner on/off comparisons, at the cost of not knowing which compound caused which change when both were active. Injection-site burden factors in regardless of philosophy: researchers administering multiple peptides subcutaneously benefit from rotating sites and letting tissue recover during off-periods, whatever the pharmacological rationale.
: Persistence depends on compound and process, and the differences are instructive. For GH secretagogues, changes mostly reverse: GH and IGF-1 return toward baseline within 1–3 weeks of discontinuation — faster for ipamorelin, slower for CJC-1295 with DAC given its long half-life — taking water retention, body-composition shifts, and insulin sensitivity changes with them as hormones normalize [PMID: 16352683]. For healing peptides the question splits: structural tissue changes — new collagen, angiogenesis, tissue remodeling — physically persist beyond withdrawal because the tissue itself has been altered, while support for ongoing processes (chronic inflammation modulation, for instance) may fade during the off-period. Weight-management compounds set the cautionary example: semaglutide discontinuation led participants to regain roughly two-thirds of lost weight within one year [PMID: 35441470], steering research toward maintenance dosing strategies rather than classic cycling.
: No controlled human study has compared cycling against continuous administration for any research peptide — full stop, and that absence defines the field. Supporting evidence stays indirect, drawn from three sources: receptor pharmacology studies demonstrating desensitization mechanisms under chronic agonist exposure, pharmacokinetic data showing sustained hormonal effects that engage feedback loops, and general endocrine principles of hypothalamic-pituitary axis regulation. The indirect case is strongest for GH secretagogues, where desensitization management is mechanistically sound even without direct human validation; weakest for healing peptides, where cycling rests on treatment timelines and design preference rather than demonstrated need. That gap doubles as an opening — researchers who document and publish cycling outcomes, both on-period effects and off-period changes, will materially advance the evidence base the entire field currently borrows against.

Summary

Three distinct rationales drive peptide cycling in research practice: receptor pharmacology (managing tachyphylaxis and hormonal feedback in secretagogues), biological timelines (matching compound exposure to the process being studied), and research design (creating on/off comparison windows for cleaner interpretation).

The published literature supports a rough hierarchy of urgency. Long-acting secretagogues like CJC-1295 with DAC generate sustained hormonal effects that engage feedback loops — structured off-periods are pharmacologically reasonable. Ipamorelin 's short half-life and selectivity lower that concern; GHRP-6 's broader receptor activity raises it again.

For BPC-157 and TB-500 , practicality outweighs pharmacology: favorable preclinical safety profiles and no classical receptor desensitization leave the research question itself to justify cycling decisions.

The field's largest gap doubles as its clearest opportunity: not one controlled human study compares cycling protocols for any research peptide. Everything here extrapolates from pharmacokinetics, mechanistic reasoning, and adjacent clinical pharmacology. Researchers who document and publish cycling outcomes — on-period effects and off-period changes alike — will write the evidence base everyone else currently lacks. For compound-specific detail, see our pages on [ BPC-157 ](/en/compounds/bpc-157/), [ TB-500 ](/en/compounds/tb-500/), [ CJC-1295 ](/en/compounds/cjc-1295/), [ Ipamorelin ](/en/compounds/ipamorelin/), and [ GHRP-6 ](/en/compounds/ghrp-6/); for managing side effects during on-periods, the Peptide Side Effects guide continues the thread.